ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 3183

Tocilizumab for the Treatment of Giant Cell Arteritis – MR-Angiography Results from the First Randomized Placebo-Controlled Trial 

Stephan Reichenbach1,2, Sabine Adler3, Jennifer Cullmann4, Harald Bonel4, Stefan Kuchen5, Felix Wermelinger1, Diana Dan1, Michael Seitz1 and Peter M. Villiger1, 1Department of Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland, 2Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, 3Rheumatology, Immunology, Allergology, University Hospital Bern, Bern, Switzerland, 4Department of Diagnostic, Interventional and Pediatric Radiology, University Hospital Bern, Bern, Switzerland, 5Rheumatology, Immunology, and Allergology, University of Bern, Bern, MD, Switzerland

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: giant cell arteritis, glucocorticoids and tocilizumab, MRI, RCT

  • Tweet
  • Email
  • Print
Session Information

Date: Wednesday, November 16, 2016

Session Title: Vasculitis IV: Diagnosis and Assessment of Disease Activity

Session Type: ACR Concurrent Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose:  As published in The Lancet online, March 4, 2016, the first randomized, placebo-controlled trial (RCT) of tocilizumab (TCZ) in giant cell arteritis (GCA) showed clinical efficacy of the anti-IL-6 receptor biologic agent in the induction and maintenance of remission for up to 52 weeks. However, very little is known about inflammatory signals in the vessel walls of TCZ-treated patients. Therefore, the aim of this analysis was to evaluate the inflammation of the vessel wall as seen on magnetic resonance angiograms (MRAs) during the RCT and to compare the signals in the two treatment arms.

Methods: In this single-center RCT participants who satisfied the 1990 American College of Rheumatology criteria were randomly assigned in a 2:1 ratio to receive either TCZ (8 mg/kg of body weight) + glucocorticoids (GC) or placebo + GC. Participants received infusions at 4-weekly intervals for 52 weeks, and GC were started at 1 mg/kg/d and then tapered down to zero. GCA was proven by positive temporal artery biopsy and/or assessed as large vessel vasculitis by MRA using a score 0 to 3; 0= no mural thickening (vessel wall diameter < 0.6 mm), no enhancement; 1= no thickening, slight mural enhancement; 2= mural thickening (> 0.6 mm), significant mural enhancement; 3= strong thickening (> 0.7 mm), strong mural and perivascular enhancement. Scores 2 and 3 were considered to represent active mural inflammation. The MRAs were analyzed by two experienced radiologists who were blinded to treatment allocation. If positive at inclusion, MRA was repeated after 3 month and at end of the study. The primary outcome for this analysis was the number of patients with complete remission on MRA based on the vasculitis score at week 12 (GC dose of 0.1 mg/kg/d). The secondary outcome was the number of patients with complete MRA remission at week 52 and the change in the vasculitis score.

Results:  Twenty-eight of 30 randomized patients underwent baseline MRA, 20 in the TCZ + GC group and 8 in the placebo + GC group. 11 MRAs at baseline (9 in the TCZ + GC group and 2 in the placebo + GC group) had no signs of vasculitis. At week 12, MRAs were performed in 9 patients in the TCZ + GC group, all of whom were in clinical remission, and 4 patients in the placebo + GC group, 2 of whom were in remission. Three (33%) patients in the TCZ + GC group were in complete MRA remission, compared to 1 (25%) in the placebo + GC group. At week 52, there was additional improvement, but no complete remission, on MRA in 3 participants in the TCZ + GC group, resulting in a median change in the vasculitis score of -1.0, and no improvement in the remaining 2 participants in the placebo + GC group, resulting in a median change in the vasculitis score of -0.5.

Conclusion:  TCZ induces and sustains clinical remission of GCA but does not completely suppress MR signals of vessel inflammation. Whether these signals are of prognostic importance remains to be determined and should be further evaluated in long-term studies.


Disclosure: S. Reichenbach, None; S. Adler, None; J. Cullmann, None; H. Bonel, None; S. Kuchen, None; F. Wermelinger, None; D. Dan, None; M. Seitz, None; P. M. Villiger, None.

To cite this abstract in AMA style:

Reichenbach S, Adler S, Cullmann J, Bonel H, Kuchen S, Wermelinger F, Dan D, Seitz M, Villiger PM. Tocilizumab for the Treatment of Giant Cell Arteritis – MR-Angiography Results from the First Randomized Placebo-Controlled Trial  [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/tocilizumab-for-the-treatment-of-giant-cell-arteritis-mr-angiography-results-from-the-first-randomized-placebo-controlled-trial/. Accessed July 1, 2022.
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tocilizumab-for-the-treatment-of-giant-cell-arteritis-mr-angiography-results-from-the-first-randomized-placebo-controlled-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies